LT3445743T - Aminorūgšties darinio provaistas - Google Patents

Aminorūgšties darinio provaistas

Info

Publication number
LT3445743T
LT3445743T LTEPPCT/JP2017/016125T LTJP2017016125T LT3445743T LT 3445743 T LT3445743 T LT 3445743T LT JP2017016125 T LTJP2017016125 T LT JP2017016125T LT 3445743 T LT3445743 T LT 3445743T
Authority
LT
Lithuania
Prior art keywords
acid derivative
aminoic acid
aminoic
derivative
acid
Prior art date
Application number
LTEPPCT/JP2017/016125T
Other languages
English (en)
Lithuanian (lt)
Inventor
Norikazu Otake
Takashi Hashihayata
Yohei Matsuda
Seiji Masuda
Yuko Yamauchi
Original Assignee
Taisho Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taisho Pharmaceutical Co., Ltd. filed Critical Taisho Pharmaceutical Co., Ltd.
Publication of LT3445743T publication Critical patent/LT3445743T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/46—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C229/50—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups and carboxyl groups bound to carbon atoms being part of the same condensed ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/45—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C255/47—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of rings being part of condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/24—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/18—All rings being cycloaliphatic the ring system containing six carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
    • C07C2602/42—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing seven carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
    • C07C2602/48—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing ten carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/58—Ring systems containing bridged rings containing three rings
    • C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
    • C07C2603/74—Adamantanes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyrrole Compounds (AREA)
LTEPPCT/JP2017/016125T 2016-04-18 2017-04-18 Aminorūgšties darinio provaistas LT3445743T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016083147 2016-04-18
PCT/JP2017/016125 WO2017183734A1 (en) 2016-04-18 2017-04-18 Prodrug of amino acid derivative

Publications (1)

Publication Number Publication Date
LT3445743T true LT3445743T (lt) 2021-09-27

Family

ID=58737797

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/JP2017/016125T LT3445743T (lt) 2016-04-18 2017-04-18 Aminorūgšties darinio provaistas

Country Status (29)

Country Link
US (2) US10464884B2 (enExample)
EP (1) EP3445743B1 (enExample)
JP (2) JP7045321B2 (enExample)
KR (1) KR102444718B1 (enExample)
CN (1) CN109071418B (enExample)
AU (1) AU2017254266B2 (enExample)
BR (1) BR112018069959B1 (enExample)
CA (1) CA3019097C (enExample)
CY (1) CY1124574T1 (enExample)
DK (1) DK3445743T3 (enExample)
ES (1) ES2886442T3 (enExample)
HR (1) HRP20211277T1 (enExample)
HU (1) HUE056046T2 (enExample)
IL (1) IL262233B (enExample)
LT (1) LT3445743T (enExample)
MX (1) MX379567B (enExample)
MY (1) MY195208A (enExample)
NZ (1) NZ747061A (enExample)
PH (1) PH12018502211A1 (enExample)
PL (1) PL3445743T3 (enExample)
PT (1) PT3445743T (enExample)
RS (1) RS62515B1 (enExample)
RU (1) RU2739318C2 (enExample)
SG (2) SG11201808387PA (enExample)
SI (1) SI3445743T1 (enExample)
SM (1) SMT202100601T1 (enExample)
TW (1) TWI738767B (enExample)
WO (1) WO2017183734A1 (enExample)
ZA (1) ZA201806444B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY195208A (en) * 2016-04-18 2023-01-11 Taisho Pharmaceutical Co Ltd Prodrug of Amino Acid Derivative
JP7314494B2 (ja) * 2017-10-17 2023-07-26 大正製薬株式会社 アミノ酸誘導体のプロドラッグを含有する医薬
JP7436385B2 (ja) * 2018-04-24 2024-02-21 ヴィーブ ヘルスケア ユーケー(ナンバー5)リミテッド Hiv成熟阻害活性を有する化合物
CN109180712B (zh) * 2018-08-08 2020-12-25 南京医科大学 一类2-茨醇的芳基硼酸酯衍生物及其应用
CN108948077B (zh) * 2018-08-09 2020-10-13 东华理工大学 一种α-磷酰化的α-氨基酸酯类化合物及其合成方法
JPWO2022114135A1 (enExample) * 2020-11-26 2022-06-02
CN112409443B (zh) * 2021-01-25 2021-04-27 潍坊科技学院 一种脯氨酸茨醇衍生物及其制备方法和在制备治疗心脑血管类疾病的药物中的应用
CN114805104B (zh) * 2021-01-29 2026-06-30 南京宁丹新药技术股份有限公司 一类氨基水杨酸类衍生物及其用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002353845A1 (en) 2001-11-23 2003-06-10 Eli Lilly And Company Prodrugs of excitatory amino acids
PL208123B1 (pl) 2001-12-27 2011-03-31 Taisho Pharmaceutical Co Ltd Pochodna kwasu 2-amino-3-alkoksy-6-fluorobicyklo [3.1.0] heksano-2, 6-dikarboksylowego, zawierająca ją kompozycja farmaceutyczna i lek, oraz jej zastosowanie
EP2123630B1 (en) 2003-06-26 2012-07-25 Taisho Pharmaceutical Co., Ltd 2-Amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative
US8642777B2 (en) 2009-11-19 2014-02-04 Taisho Pharmaceutical Co., Ltd Process for producing 3-alkoxy-2-amino-6-fluorobicyclo [3.1.0] hexane-2,6-dicarboxylic acid derivative and intermediate thereof
CN103209954B (zh) * 2010-11-18 2015-09-02 伊莱利利公司 作为mGluR2/3拮抗剂的4-取代的-3-苄氧基-双环[3.1.0]己烷化合物
AR083845A1 (es) 2010-11-18 2013-03-27 Lilly Co Eli COMPUESTOS 3-FENILSULFANILMETIL-BICICLO[3.1.0]HEXANO 4-SUSTITUIDOS COMO ANTAGONISTAS DE mGluR2/3
WO2013062680A1 (en) 2011-10-25 2013-05-02 Braincells, Inc. Novel compounds and compositions thereof for treating nervous system disorders
EP2857385B1 (en) * 2012-06-01 2017-08-02 Taisho Pharmaceutical Co., Ltd. Prodrug of fluorine-containing amino acid
WO2015065983A1 (en) 2013-10-29 2015-05-07 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of gastrointestinal infections
MY195208A (en) * 2016-04-18 2023-01-11 Taisho Pharmaceutical Co Ltd Prodrug of Amino Acid Derivative

Also Published As

Publication number Publication date
US10464884B2 (en) 2019-11-05
PT3445743T (pt) 2021-08-24
AU2017254266B2 (en) 2021-03-11
SG11201808387PA (en) 2018-10-30
CY1124574T1 (el) 2022-07-22
WO2017183734A1 (en) 2017-10-26
US20190047943A1 (en) 2019-02-14
MX379567B (es) 2025-03-11
HRP20211277T1 (hr) 2021-11-12
RU2739318C2 (ru) 2020-12-22
US20190337887A1 (en) 2019-11-07
PL3445743T3 (pl) 2021-12-20
SI3445743T1 (sl) 2021-11-30
KR102444718B1 (ko) 2022-09-16
EP3445743A1 (en) 2019-02-27
TWI738767B (zh) 2021-09-11
DK3445743T3 (da) 2021-10-18
JP7045321B2 (ja) 2022-03-31
EP3445743B1 (en) 2021-08-04
HUE056046T2 (hu) 2022-01-28
CN109071418A (zh) 2018-12-21
JP2019513755A (ja) 2019-05-30
RU2018140250A3 (enExample) 2020-06-23
BR112018069959A2 (pt) 2019-02-05
ES2886442T3 (es) 2021-12-20
SG10202006019YA (en) 2020-08-28
JP2021063095A (ja) 2021-04-22
MY195208A (en) 2023-01-11
PH12018502211A1 (en) 2019-10-21
ZA201806444B (en) 2020-01-29
AU2017254266A1 (en) 2018-10-25
MX2018012442A (es) 2019-02-21
RS62515B1 (sr) 2021-11-30
BR112018069959B1 (pt) 2023-01-17
RU2018140250A (ru) 2020-05-19
IL262233A (en) 2018-11-29
IL262233B (en) 2021-09-30
CA3019097C (en) 2023-08-29
KR20180134892A (ko) 2018-12-19
US10689327B2 (en) 2020-06-23
SMT202100601T1 (it) 2021-11-12
CN109071418B (zh) 2022-03-18
NZ747061A (en) 2021-07-30
CA3019097A1 (en) 2017-10-26
TW201803842A (zh) 2018-02-01

Similar Documents

Publication Publication Date Title
NL301360I2 (nl) talquetamab
EP3502950A4 (en) MULTIPLIER-ACC
DK3319956T3 (da) Substituerede oxopyridinderivater
EP3440949A4 (en) FLAVOR INHALER
LT3457851T (lt) Sobetiromo dariniai
LT3402792T (lt) Chinolin-2-ono dariniai
EP3402022A4 (en) GRAB WIRE
EP3465295A4 (en) STACK OF POLARIZERS
LT3371168T (lt) Indolin-2-ono dariniai
DK3438103T3 (da) Griseofulvinforbindelse
EP3351087A4 (en) HARVESTER
EP3309163A4 (en) SUBSTITUTED DIHYDROPYRROLO PYRAZOL DERIVATIVE
EP3551020A4 (en) FEET WASHING MACHINE
DK3509963T3 (da) Pallecontainer
DK3347403T3 (da) Polyalkoxyfedtforbindelse
EP3490399A4 (en) INTERCONNECTS
EP3444345C0 (en) MICRO-143 RNA DERIVATIVE
DE112017000734A5 (de) Glycolsensor
DK3323708T3 (da) Bovfender
DK3295800T3 (da) Sandwichkiksindretning
DK3452587T3 (da) Penicillin-g-acylaser
EP3682742C0 (en) ALLULOSE CARAMEL
EP3491440A4 (en) ADAPTER BLOCK ASSEMBLY
HUE048290T2 (hu) Fûszertermék
DK3312181T3 (da) Imidazodiazepinforbindelse